Page 14 - Stevene Nissen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

United statesMilind desaiStevene nissenBristol myers squibbEli lillyEmily hendersonCleveland clinic coordinating centerHypertrophic cardiomyopathy centerClinical researchVascular thoracic institute at cleveland clinicAmerican college of cardiologyMyokardia incCleveland clinic heart vascular thoracic instituteNovo nordiskCleveland clinic ledMyosin inhibition

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels | Cardiology | JAMA

This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein

United statesUnited kingdomEteläuomen läiCity ofDaiichi sankyoStevene nissenJacksonville centerCleveland clinic coordinating centerDrug administrationSilence therapeuticsStudy organizationLaboratory medicine reference material for lpClinical researchInstitute incNovo nordiskAmerican indian

APOLLO: Short Interfering RNA Shows Promise for Reducing Lipoprotein(a) - American College of Cardiology

APOLLO: Short Interfering RNA Shows Promise for Reducing Lipoprotein(a) - American College of Cardiology
acc.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acc.org Daily Mail and Mail on Sunday newspapers.

United kingdomStevene nissenAdvanced lipid testing

Silence Therapeutics plc: Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC 22) Annual Meeting

SLN360 reduced Lp(a) a key genetic risk factor for heart disease by up to 98% with reductions of up to 81% persisting at 150 days Results were simultaneously published in The Journal of the American

United statesUnited kingdomGiles campionMary conwayStevene nissenHansoh pharmaMallinckrodt pharmaceuticalsThoracic institute at cleveland clinicAmerican college of cardiologyJournal of the american medical associationExchange commissionCorporate communicationsAmerican medical associationPlacebo controlled double blind dose rangingLate breaking science sessionAmerican college

APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

The results add to growing enthusiasm for achieving the holy grail of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.

United statesUnited kingdomDaiichi sankyoPamelab morrisStevene nissenVera bittnerEli lillyUniversity of alabama at birminghamUniversity of cambridgeSanofi aventisUniversity of south carolinaEuropean society of cardiologyBristol myers squibbGilead sciencesMedicines companyAmerican college of cardiology